

Submission from British Association for Psychopharmacology.
Re: Naltrexone HTA Assessment

This report, from a practising clinician's perspective, reflects clinical experience. It confirms that the evidence and benefit of naltrexone are variable and, critically, implies that it is specific sub-groups that are most likely to benefit but admits that the evidence does not yet exist to determine what these sub-groups are. Given the above and its slight use (both in terms of absolute use and economic cost) the group's finding that it should continue to be used makes sense.